Longer PFS and higher ORR for frailty patients with R/R Multiple Myeloma treated with PVd than Vd

OPTIMISM trial has previously demonstrated that pomalidomide (P) in combination with bortezomib + dexamethasone (Vd) significantly improved PFS in lenalidomide–pretreated patients with RRMM versus bortezomib + dexamethasone (Vd). In this MEDtalk, Professor of Medicine Paul G. Richardson, presents data from a subanalysis of OPTIMISM trial of frailty patients with relapsed/refractory multiple myeloma.